House Bill 525 revises North Carolina’s Advisory Council on Rare Diseases, also referred to in the bill as Taylor’s Law. The bill moves the council from the University of North Carolina at Chapel Hill School of Medicine to the Department of Health and Human Services, updates the council’s membership structure, and clarifies its duties. The council is intended to advise the Governor, the Secretary of Health and Human Services, and the General Assembly on rare disease research, diagnosis, treatment, education, public awareness, and related policy issues.
The bill expands and rebalances the council’s membership to include a broad mix of medical professionals, researchers, patients, caregivers, advocates, insurers, Medicaid managed care representation, and legislative appointees. It also revises term lengths, vacancy procedures, meeting rules, and administrative support responsibilities so that DHHS rather than UNC provides support services. The council’s reporting duties remain in place, including annual reports to state officials and legislative staff on findings, recommendations, and potential statutory changes.
H525 also appropriates recurring General Fund money to DHHS: $250,000 for fiscal year 2025-2026 and $250,000 for fiscal year 2026-2027. These funds are designated to cover the council’s operating expenses, giving the reorganized council a dedicated funding stream and making the council’s work a continuing state obligation rather than an unfunded advisory function.
The overall sentiment reflected by the bill’s structure is supportive of rare disease patients and families, with an emphasis on coordination, expertise, and sustained state attention. Although no committee transcript or recorded vote is provided, the bill’s sponsors and detailed membership design suggest a policy consensus around improving rare disease awareness, treatment access, and interagency coordination. The bill appears aimed at strengthening an existing advisory body rather than creating a new program from scratch.
The main points of potential contention are likely to be the transfer of the council from UNC to DHHS, the scope of state spending, and the breadth of representation on the council, including insurer, Medicaid managed care, and industry members. Those choices may raise questions about administrative control, balance among patient and payer interests, and whether recurring appropriations are justified. The bill also touches on how rare disease policy should be coordinated across state agencies and whether the council should have a stronger role in shaping Medicaid and drug policy.
The bill amends Chapter 130A to reorganize the Advisory Council on Rare Diseases, changing its placement, membership, administrative support, reporting structure, and duties. It transfers the council to the Department of Health and Human Services, updates statutory references, and requires DHHS to provide support services. It also appropriates recurring General Fund dollars to DHHS for council operations, creating a direct fiscal impact on state spending and establishing ongoing funding for the council’s work.
The bill appears generally favorable and policy-driven, with a clear emphasis on supporting rare disease patients, caregivers, and medical experts. Its design suggests broad support for improving coordination, awareness, and treatment resources. No recorded opposition, transcript debate, or vote history is provided, so the available context does not show active controversy, only the kinds of administrative and fiscal questions that could arise from the proposal.
Likely areas of contention include whether the council should remain tied to UNC or be moved to DHHS, whether recurring appropriations are appropriate, and how much influence insurers, Medicaid managed care plans, and industry representatives should have on the council. Some stakeholders may also question the balance between patient-centered representation and institutional or payer interests. The bill’s expanded advisory role in policy, research, and treatment coordination could also draw scrutiny from agencies or advocates concerned about scope and authority.